{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Yan M"],"pubmed_abstract":["<h4>Background</h4>Elderly patients with relapsed acute myeloid leukemia (AML) have limited treatment options and a poor prognosis. Venetoclax combined with azacitidine has shown promising activity in newly diagnosed or relapsed/refractory AML, but real-world data on older populations remain scarce. This study aimed to evaluate the efficacy, safety, and prognostic factors - including select blood biomarkers - of venetoclax plus azacitidine in elderly patients with relapsed AML.<h4>Methods</h4>We conducted a single-center retrospective review of patients aged ≥65 years diagnosed with relapsed AML who received venetoclax plus azacitidine between January 2018 and December 2022. Patient demographics, baseline disease characteristics, and treatment details were collected. Blood biomarkers, such"],"journal":["Mediterranean journal of hematology and infectious diseases"],"pagination":["e2025058"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12422247"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of Venetoclax Combined with Azacitidine in Elderly Patients with Relapsed Acute Myeloid Leukemia."],"pmcid":["PMC12422247"],"pubmed_authors":["Yan M","Xu L","Wang G","Wang J"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Venetoclax Combined with Azacitidine in Elderly Patients with Relapsed Acute Myeloid Leukemia.","description":"<h4>Background</h4>Elderly patients with relapsed acute myeloid leukemia (AML) have limited treatment options and a poor prognosis. Venetoclax combined with azacitidine has shown promising activity in newly diagnosed or relapsed/refractory AML, but real-world data on older populations remain scarce. This study aimed to evaluate the efficacy, safety, and prognostic factors - including select blood biomarkers - of venetoclax plus azacitidine in elderly patients with relapsed AML.<h4>Methods</h4>We conducted a single-center retrospective review of patients aged ≥65 years diagnosed with relapsed AML who received venetoclax plus azacitidine between January 2018 and December 2022. Patient demographics, baseline disease characteristics, and treatment details were collected. Blood biomarkers, such","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-02T20:28:15.038Z","creation":"2026-04-20T03:09:59.416Z"},"accession":"S-EPMC12422247","cross_references":{"pubmed":["40937311"],"doi":["10.4084/MJHID.2025.058"]}}